透雲生物
Ty Biotech

Touyun Biotech Group Limited
透雲生物科技集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 1332)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO 2024 ANNUAL REPORT AND QUARTERLY UPDATE ON THE IMPLEMENTATION OF ACTION PLAN TO RESOLVE THE AUDIT QUALIFICATION

This announcement is made by the board (the "**Board**") of directors (the "**Directors**") of Touyun Biotech Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the annual report of the Company for the year ended 31 December 2024 (the "**2024 Annual Report**"). Unless otherwise stated, capitalised terms used herein shall have the same meanings as those defined in the 2024 Annual Report.

In addition to the information provided in the 2024 Annual Report, the Board would like to provide further information to the paragraph headed "Mitigation measures to resolve the Audit Qualification" under the section headed "Going Concern and Mitigation Measures" in the 2024 Annual Report.

Quarterly update on the implementation of mitigation measures to resolve the Audit Qualification

Since the date of the 2024 Annual Report and until the date of this announcement, the Group has been taking active measures and made progress in mitigating the liquidity burden and improving the financial position with a view to resolving the Audit Qualification, the details of which are summarised as follows:

1. The Company is currently launching a series of new health products targeting different customer groups for the purpose of continuously expanding the Group's customers base and stream of revenue. The Board considers that there is growth potential for the Group's health products market as the population becomes more health conscious.

2. On 1 April 2025, Mr. Wang Liang, a Director, and Ms. Qiao Yanfeng, a shareholder of the Company, provided undertakings to the Company, confirming that they would not demand repayment of the amounts due to them with aggregate amounts of approximately HK$121.8 million until the Group has sufficient cash reserve to repay the amounts due to them.

3. The Company had successfully obtained a new loan of HK$2.3 million from Mr. Wang Liang for the use of the Group's working capital.

4. The Company had successfully obtained to obtain new loans with an aggregate principal amount of approximately HK$28.0 million from several borrowers.

5. Starting from May 2025, the Group has been negotiating with one of its borrowers (the "**Borrower**") for the extension of term of a loan with a principal amount of RMB60million and maturity date of 7 June 2025. As at the date of the announcement, the Borrower had indicated its willingness negotiate for an extension of the maturity date of such loan and no debt recovery action will be taken in the course of the negotiation.

6. The Company has been exploring various options and alternatives to increase the Group's working capital by realisation of the Group's non-core asset items and unprofitable business. For example, the Group entered into agreements for the disposal of 30% and 70% shares in one of its subsidiaries to an independent third-party investor at the consideration of RMB5,000,000 and RMB13,000,000 on 6 March 2025 and 6 May 2025 respectively. Upon completion of the abovementioned disposals, the Group is expected to record unaudited gain on disposal of approximately HK$6,000,000 and HK$15,300,000 respectively. Please refer the Company's announcement dated 6 March 2025 and 6 May 2025 and the Company's circular dated 28 May 2025 for further details of the abovementioned disposals.

7. The Group has been taking active initiatives with a view to enhance the speed of the Group's product distribution and customer reach-out: (i) the Group has been maintaining ongoing discussions with leading supermarket chains/groups, with mutual interest in establishing a formal agreement for the distribution and sale of products of the Group; and (ii) the Group has been keeping an eye on and collaborating with various trending Key Opinion Leaders to promote the Group's products and boost product sales through livestream commerce channels.

The above information is supplemental to the 2024 Annual Report and does not affect other information in the 2024 Annual Report. Save as disclosed in this announcement, the contents of the 2024 Annual Report remain unchanged.

The shareholders of the Company and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board
Touyun Biotech Group Limited
Wang Liang
Chairman

Hong Kong, 30 June 2025

As at the date of this announcement, the Board comprises the following directors:

Executive Directors
Mr. Wang Liang *(Chairman)*
Mr. Du Dong

Non-executive Directors
Mr. Chen Hui
Ms. Tian Yuze
Mr. Zhang Lele

Independent Non-executive Directors
Mr. Cheung Wing Ping
Mr. Ha Kee Choy Eugene
Mr. To Shing Chuen